Cas:104614-74-6 [2,6-dichloro-4-(trifluoromethylsulfonyl)phenyl]hydrazine manufacturer & supplier

Chemical Name:[2,6-dichloro-4-(trifluoromethylsulfonyl)phenyl]hydrazine

CAS.NO:104614-74-6

Synonyms:2,6-Dichloro-4-(trifluoromethylsulfonyl)phenylhydrazine;2,5-DIBROMO-3,6-DIFLUOROBENZEN;Hydrazine,[2,6-dichloro-4-[(trifluoromethyl)sulfonyl]phenyl]

Molecular Formula:C₇H₅Cl₂F₃N₂O₂S

Molecular Weight:309.09300

HS Code:2928000090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:80.57000

Exact Mass:307.94000

LogP:4.42660

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2,6-Dichloro-4-(trifluoromethylsulfonyl)phenylhydrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Hydrazine,[2,6-dichloro-4-[(trifluoromethyl)sulfonyl]phenyl] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Hydrazine,[2,6-dichloro-4-[(trifluoromethyl)sulfonyl]phenyl] Use and application,2,5-DIBROMO-3,6-DIFLUOROBENZEN technical grade,usp/ep/jp grade.

Related News: During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. [2,6-dichloro-4-(trifluoromethylsulfonyl)phenyl]hydrazine manufacturer In a memo to Branchburg employees on May 20, Nellie Clark, head of the plant, summed up the outside lawyers’ findings: “In the end and very importantly, allegations that Lilly made false statements to the FDA were not substantiated.” [2,6-dichloro-4-(trifluoromethylsulfonyl)phenyl]hydrazine supplier The term active pharmaceutical ingredient may refer to an active chemical within an FDA-regulated drug, or API might mean the entire drug with its active and inactive ingredients. [2,6-dichloro-4-(trifluoromethylsulfonyl)phenyl]hydrazine vendor During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. [2,6-dichloro-4-(trifluoromethylsulfonyl)phenyl]hydrazine factory The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.